Literature DB >> 11107051

Clinicopathological characteristics of atypical cystic duct (ACD) of the breast: assessment of ACD as a precancerous lesion.

R Kusama1, M Fujimori, I Matsuyama, L Fu, K Ishii, Y Hama, K Asanuma, K Shingu, S Kobayashi, S Tsuchiya.   

Abstract

To clarify the clinicopathological features of an atypical cystic duct (ACD) as defined by Tsuchiya's criteria as a precancerous lesion of the breast, we used 200 whole mammary gland serial sections of breast cancer. Forty-four (22%) of the 200 breast cancer patients had ACD breast lesions. The frequency of patients with ACD increased in premenopausal women (P = 0.001). There was no correlation between the ACD-present group and the ACD-absent group for immunohistochemical status of the estrogen receptor (ER), progesterone receptor (PgR), p53, or c-erbB2; Ki-67 labeling index of cancer tissues; size of tumor, or lymph node metastases. A number of ACD lesions displayed continuity to cancer lesions. In 500 serial sections of a paraffin-embedded tissue of a ACD case at 3 microm intervals, an apparent transition from ACD into ductal carcinoma in situ was observed. Immunohistochemical analysis using alpha-smooth muscle actin showed that myoepithelial cells of ACD stained strongly, and their nuclei and cytoplasm were thinning. In 16 of the 44 (36%) ACD-present patients, carcinoma cells stained positive for p53. Within those 16 cases, 12 cases (75%) were positive for p53 in ACD lesions. There was a significant correlation between the expression of p53 protein in malignant cells and ACD (P = 0.001). All 44 ACD lesions had no staining of c-erbB2, regardless of staining in malignant lesions. The mean Ki-67 labeling index of ACD lesions was low (0.3%), suggesting that ACD had a low proliferative rate. We suggest that ACD is the precancerous breast lesion because of a histologic continuum between ACD and malignancy, and because of p53 protein expression in ACD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11107051     DOI: 10.1046/j.1440-1827.2000.01121.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  8 in total

Review 1.  The molecular pathology of breast cancer progression.

Authors:  Alessandro Bombonati; Dennis C Sgroi
Journal:  J Pathol       Date:  2010-11-16       Impact factor: 7.996

2.  Estrogen effects on epithelial proliferation and benign proliferative lesions in the postmenopausal primate mammary gland.

Authors:  Charles E Wood; Joy M Hester; Susan E Appt; Kim R Geisinger; J Mark Cline
Journal:  Lab Invest       Date:  2008-07-07       Impact factor: 5.662

Review 3.  Preinvasive breast cancer.

Authors:  Dennis C Sgroi
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

4.  A case of solitary intraductal papilloma of the breast coexisting with ductal carcinoma in situ (DCIS).

Authors:  Nobuyuki Takemoto; Hiroshi Yamamoto; Katsuko Shiraishi; Junko Koike
Journal:  J Med Ultrason (2001)       Date:  2007-03-15       Impact factor: 1.314

5.  Flat epithelial atypia and risk of breast cancer: A Mayo cohort study.

Authors:  Samar M Said; Daniel W Visscher; Aziza Nassar; Ryan D Frank; Robert A Vierkant; Marlene H Frost; Karthik Ghosh; Derek C Radisky; Lynn C Hartmann; Amy C Degnim
Journal:  Cancer       Date:  2015-01-13       Impact factor: 6.860

6.  [Flat epithelial neoplasia and other columnar cell lesions of the breast].

Authors:  F R Fritzsche; M Dietel; G Kristiansen
Journal:  Pathologe       Date:  2006-09       Impact factor: 1.011

7.  Flat epithelial atypia with and without atypical ductal hyperplasia: to re-excise or not. Results of a 5-year prospective study.

Authors:  Ikechukwu Uzoaru; Bradley R Morgan; Zheng G Liu; Frank J Bellafiore; Farah S Gaudier; Jeanne V Lo; Kourosh Pakzad
Journal:  Virchows Arch       Date:  2012-09-08       Impact factor: 4.064

Review 8.  Are Columnar Cell Lesions the Earliest Non-Obligate Precursor in the Low-Grade Breast Neoplasia Pathway?

Authors:  Sarah Strickland; Gulisa Turashvili
Journal:  Curr Oncol       Date:  2022-08-11       Impact factor: 3.109

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.